For the treatment of cardiovascular diseases such as hypertension, cerebral ischemia, vascular inflammation, arteriosclerosis, atherosclerosis, coronary vasospasm, and stroke, ROCK2 was used as therapeutic drug target because ROCK2 inhibit myosin binding subunit (MBS) of MLCP to regulate MLC’s phosphorylation at Ser19 residue instead of dephosphorylation and cause calcium independent contraction instead of relaxation. Here, MLC1 is linked to hypertensive disorder.